Alluvi, initially dubbed LY3414901, represents a exciting advancement in obesity management. This dual -action glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) target agonist https://alluvi022793.articlesblogger.com/65808653/alluvi-a-deep-dive-into-retatrutide-s-potential